Search

Abstract: 90Y-labelled radiopharmaceuticals offer promising prospects for radionuclide therapies of tumours, e.g. radioimmunotherapies (RIT), (), peptide receptor radiotherapies (PRRT), (), and selective internal radiotherapies (SIRT), (). 90Y, an almost pure high-energy beta radiation emitter (Eβ,max = 2.28 MeV), is a favourable radionuclide for therapeutic purposes. However, when preparing and performing these therapies, high activities of 90Y (>1 GBq) are to be manipulated and technicians, physicians and nurses may receive high skin exposures to the hands. If radiation protection standards are low, the exposure of staff can exceed the annual skin dose limit of 500 mSv. Within a particular work package (WP4) of the ORAMED project, comprehensive measurements in nuclear medicine departments of several hospitals in 6 European countries were carried out. The study focussed on 90Y-labelled substances such as Zevalin® and DOTATOC to achieve a representative database on staff exposure. This paper summarises the most important results and conclusions for individual monitoring of skin exposure of staff. [Copyright &y& Elsevier]

For the first time, a comparison of radon activity concentration in air has been performed within the scope of Euromet. In the project 657, 'Comparison of calibration facilities for the radon activity concentration,' 12 participants from 9 countries compared different radon reference atmospheres at 1, 3 and 10 k Bq m-3 via a transfer standard. The comparison was listed as BIPM supplementary comparison EUROMET.RI(II)-S1. The results of most participants are correlated due to common traceability to one single radon gas standard producer. This makes a careful correlation analysis necessary to achieve an appropriate comparison reference value. The results of the comparison as well as the complex analysis of the correlated set of data is presented and discussed.